To estimate the prevalence of good adherence to statin monotherapy and identify demographic and clinical factors associated with adherence among adults prescribed lipid-lowering therapy for the prevention of atherosclerotic cardiovascular disease, highlighting its importance in reducing cardiovascular risk.
Key Findings:
Pooled prevalence of good adherence was 62.4%, with lower adherence in primary prevention (57.5%) compared to secondary prevention (64.4%), both statistically significant.
Lower adherence associated with female sex, Black race, smoking, depression, and heart failure, all statistically significant.
Higher adherence observed among older adults, those with myocardial infarction, hypertension, multiple comorbidities, and patients on polypharmacy.
Interpretation:
Statin adherence remains suboptimal and is influenced by various demographic and clinical factors, highlighting the need for targeted strategies to improve adherence, especially in high-risk groups.
Limitations:
Primary non-adherence was not reported in any included study, which may underestimate overall adherence rates.
Variability in adherence measurement methods across studies limits comparability and generalizability.
Conclusion:
Targeted interventions are urgently necessary to improve statin adherence, particularly among populations at higher risk for atherosclerotic cardiovascular disease.
by Athanasios Basios, Georgios Markozannes, Evangelia E Ntzani, Konstantinos Christopoulos, Christina A Chatzi, Evangelos Liberopoulos, Konstantinos K Tsilidis, Maria Pappa, Evangelos C Rizos
Pregnant patients who sat less and moved more at light intensity had a lower risk of adverse outcomes in a prospective cohort study, but the findings do not prove causation.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
